Last updated: September 7, 2026
CROFAB is a high-value, low-volume antivenom used for North American pit-viper envenomation. Its market is driven by emergency medical need, hospital stocking requirements, seasonal snakebite incidence, and limited manufacturing capacity rather than routine prescription demand. BTG developed and commercialized CROFAB before selling its Specialty Pharmaceuticals business to SERB Pharmaceuticals in 2021 for approximately $262 million. CROFAB-specific revenue has not been separately disclosed in SERB’s public financial reporting, limiting precise product-level valuation.
What is CROFAB and how does its market work?
CROFAB is an intravenous, ovine-derived Fab antivenom approved by the FDA in 2000 for envenomation by North American crotalid snakes, including rattlesnakes, copperheads, and cottonmouths. The product is manufactured from antibodies generated in sheep immunized with North American pit-viper venom and purified into antibody fragments.[1]
The commercial market has four defining characteristics:
| Market characteristic |
Effect on CROFAB |
| Low incidence but high medical severity |
Hospitals must maintain inventory despite irregular utilization |
| Emergency-only use |
Demand is relatively price-insensitive at the point of treatment |
| Seasonal case concentration |
Sales and replenishment rise during warmer months |
| Complex biological manufacturing |
New competitors face long development and supply-chain requirements |
The United States records roughly 7,000 to 8,000 venomous snakebites annually, although the number of clinically significant envenomations requiring antivenom is lower.[2] CROFAB demand is concentrated in the Southeast, Southwest, and other regions with significant rattlesnake, copperhead, and cottonmouth populations.
How hospitals purchase CROFAB
Hospitals typically purchase through pharmaceutical wholesalers, group purchasing organizations, or direct specialty-pharmacy channels. Emergency departments, trauma centers, rural hospitals, and regional referral hospitals must balance two risks:
- Holding expensive inventory that may expire before use.
- Maintaining insufficient stock during a time-critical envenomation.
This creates a stocking market in which availability and contract terms can be as important as unit price. Demand can rise abruptly after local snakebite clusters, severe weather, outdoor activity, or increased emergency-department utilization.
How has CROFAB’s financial trajectory developed?
CROFAB was one of BTG’s most commercially important specialty-pharmaceutical products before the company’s sale to SERB. BTG’s Specialty Pharmaceuticals portfolio also included products such as DigiFab and Voraxaze, making product-level CROFAB revenue difficult to isolate from public annual reports.[3]
The financial trajectory can be divided into four periods:
| Period |
Commercial development |
Financial implication |
| 2000-2010 |
FDA approval and market establishment |
CROFAB became a primary U.S. antivenom product |
| 2011-2017 |
Higher pricing and specialty-pharma expansion |
Revenue benefited from strong per-treatment economics |
| 2018-2020 |
Competition from ANAVIP and BTG corporate events |
Pricing and share faced greater pressure |
| 2021-present |
Ownership transferred to SERB |
Product remained strategically important, but standalone sales are not publicly reported |
BTG disclosed Specialty Pharmaceuticals as a business segment but did not consistently provide a complete, audited CROFAB revenue series. As a result, product-specific revenue estimates circulating in market commentary should be treated as estimates rather than reported financial data.
The 2021 sale transferred CROFAB and related Specialty Pharmaceuticals assets to SERB. The transaction value of approximately $262 million provides a reference point for the portfolio’s strategic value, but it is not a CROFAB standalone valuation.[4]
What drives CROFAB revenue?
CROFAB revenue depends on:
- Number of clinically significant snakebites.
- Number of vials administered per patient.
- Hospital stocking levels.
- Product wastage and expiration.
- Contract pricing and wholesaler discounts.
- Availability of competing antivenom.
- Emergency-department treatment protocols.
- Regional incidence of rattlesnake and copperhead bites.
The number of vials used per patient varies substantially. Mild cases may require only a limited initial dose, while severe envenomation can require repeated dosing to control swelling, coagulopathy, or systemic toxicity. Treatment guidelines and the FDA label permit additional dosing when clinical control is not achieved.[1]
How does CROFAB compare with ANAVIP?
ANAVIP is CROFAB’s principal branded U.S. competitor. It is an equine-derived F(ab')2 antivenom approved by the FDA in 2018 for North American pit-viper envenomation.[5]
| Attribute |
CROFAB |
ANAVIP |
| Active antibody format |
Ovine Fab |
Equine F(ab')2 |
| FDA approval |
2000 |
2018 |
| Manufacturer history |
BTG, now SERB |
Rare Disease Therapeutics |
| Primary clinical role |
Broad North American crotalid coverage |
North American pit-viper envenomation |
| Antibody persistence |
Shorter Fab half-life |
Longer F(ab')2 persistence |
| Commercial position |
Established incumbent |
Competitive alternative |
| Main market advantage |
Familiarity, distribution, broad installed base |
Potentially lower repeat dosing and longer persistence |
CROFAB benefited from more than 15 years of market familiarity before ANAVIP launched. ANAVIP’s longer antibody persistence may reduce the need for repeat dosing in some patients, although treatment decisions depend on the snake species, severity of envenomation, clinical response, and institutional protocol.
Competition has two financial effects. First, hospitals can negotiate more aggressively when two branded antivenoms are available. Second, pharmacy and therapeutics committees can compare total treatment cost rather than vial price alone. The relevant economic metric is the cost of achieving clinical control, including repeat dosing, monitoring, wastage, and adverse-event management.
What is the FDA regulatory status of CROFAB?
CROFAB was approved under FDA New Drug Application 020807 in 2000.[1] It is regulated as a drug under the Federal Food, Drug, and Cosmetic Act rather than as a biologic license product under the Public Health Service Act.
That distinction matters for follow-on competition. CROFAB does not use the standard biosimilar pathway associated with products licensed under the Public Health Service Act. A competing developer would more likely evaluate a complex 505(b)(2) or other evidence-intensive pathway, depending on product composition, manufacturing process, clinical data, and FDA classification.
CROFAB’s regulatory position includes:
- Approved indication for North American crotalid envenomation.
- Animal-derived antibody-fragment manufacturing.
- Intravenous administration after reconstitution.
- Cold-chain storage requirements.
- Product-specific immunogenicity and hypersensitivity considerations.
- Clinical-use decisions based on active envenomation rather than prophylaxis.
FDA-approved labeling identifies potential adverse reactions including hypersensitivity and serum sickness, which can affect hospital formularies and post-treatment monitoring.[1]
What patents and exclusivity protect CROFAB?
CROFAB’s primary commercial protection now comes from manufacturing complexity, clinical familiarity, regulatory history, supply reliability, and hospital procurement relationships rather than obvious remaining market exclusivity.
The product received FDA approval in 2000. Any original small-molecule-style new chemical entity exclusivity would have expired long ago. CROFAB’s age also means that any early composition or manufacturing patents would generally have reached their ordinary statutory terms unless extended or supported by later-issued claims.
CROFAB is not a conventional small-molecule product for which an ANDA pathway is straightforward. A competitor would face potential barriers involving:
- Venom-antigen selection.
- Immunization of source animals.
- Antibody purification.
- Batch consistency.
- Neutralization breadth across snake species.
- Viral and adventitious-agent controls.
- Potency assays.
- Clinical bridging.
- FDA review of manufacturing comparability.
No verified current patent number is required to explain CROFAB’s principal competitive protection. The practical barrier is the integrated manufacturing and regulatory package. Publicly reported information does not establish a current, product-determinative patent estate that would independently block competition.
Are there Paragraph IV challenges or CROFAB patent lawsuits?
No major publicly documented Paragraph IV campaign or settlement involving CROFAB is established in the cited FDA and corporate sources. This is consistent with the product’s unusual regulatory profile. CROFAB is an animal-derived antivenom with complex manufacturing requirements, not a high-volume oral medicine that naturally attracts multiple ANDA filers.
A generic launch would therefore be more likely to depend on:
- FDA acceptance of the regulatory pathway.
- Demonstration of comparable neutralization activity.
- Manufacturing validation.
- Adequate supply of venom and immunized-source material.
- Hospital adoption and stocking economics.
The absence of a large Paragraph IV record does not eliminate competitive risk. It indicates that competition is more likely to arise through a new or alternative antivenom product than through a conventional generic substitution model.
What manufacturing barriers affect CROFAB?
Manufacturing is a material barrier to entry. CROFAB requires controlled production of antibodies generated against multiple pit-viper venoms. A new manufacturer must establish reliable access to venom, qualified animals, validated immunization protocols, purification capacity, potency testing, and cold-chain distribution.
Key barriers include:
- Limited qualified antivenom manufacturing infrastructure.
- Long development timelines for animal-derived products.
- Batch-to-batch variability.
- Need for species-specific neutralization data.
- FDA scrutiny of animal-derived raw materials.
- High cost of maintaining low-volume production capacity.
- Inventory expiration risk.
- Emergency supply obligations.
These barriers reduce the probability that a price-focused entrant will immediately replicate CROFAB’s market position. They also support premium pricing compared with ordinary injectable drugs.
What is the geographic coverage of CROFAB?
CROFAB’s commercial market is primarily the United States. Demand is highest in states with substantial populations of rattlesnakes, copperheads, cottonmouths, and related crotalid species.
Regional demand is shaped by:
- Snake habitat.
- Outdoor recreation.
- Agricultural and construction activity.
- Rural hospital density.
- Transfer patterns to tertiary medical centers.
- State poison-control and emergency-care protocols.
CROFAB’s label is designed for North American crotalid envenomation. International markets use different antivenoms because snake species, venom profiles, regulatory requirements, and treatment protocols differ by geography.
What generic launch risks exist for CROFAB?
A near-term conventional generic launch risk appears lower than for a standard tablet or injectable small molecule. The most credible competitive risks are:
| Risk |
Probability profile |
Commercial effect |
| ANAVIP share expansion |
Immediate and ongoing |
Pricing pressure and formulary switching |
| New antivenom entrant |
Medium-term |
Could reduce hospital dependence on CROFAB |
| Hospital purchasing consolidation |
Ongoing |
Lower net prices and larger contract discounts |
| Manufacturing interruption |
Event-driven |
Temporary price and allocation volatility |
| Clinical protocol changes |
Medium-term |
Could alter vial utilization |
| FDA pathway innovation |
Long-term |
Could reduce barriers for follow-on products |
CROFAB’s strongest defense is its installed base. Emergency physicians, toxicologists, pharmacists, and hospitals already understand the product’s use, dosing, and procurement process. Its weakest defense is the availability of an alternative branded antivenom with a differentiated antibody format.
How exposed is SERB to CROFAB revenue?
CROFAB is strategically important to SERB because it fits the company’s specialty-pharmaceutical focus and has a defensible hospital-based market. The product’s revenue quality is mixed:
- Gross margins can be attractive because of specialty pricing.
- Demand is irregular and seasonally concentrated.
- Inventory requirements consume working capital.
- Product expiration can create write-offs.
- Competition can reduce net pricing.
- Product-level revenue concentration can increase operational risk.
Because SERB is privately held and does not provide the same level of segment disclosure as a public company, CROFAB revenue, EBITDA, annual unit volume, and net price are not reliably available as standalone metrics. The $262 million BTG Specialty Pharmaceuticals transaction is the clearest public valuation reference, but it covers a portfolio rather than CROFAB alone.[4]
Key Takeaways
- CROFAB is an established U.S. antivenom with high revenue per treated patient and low annual unit volume.
- Its market is driven by emergency need, hospital stocking, seasonality, and regional snakebite incidence.
- SERB acquired BTG’s Specialty Pharmaceuticals business, including CROFAB, for approximately $262 million in 2021.
- CROFAB-specific revenue and profitability are not separately disclosed in public SERB reporting.
- ANAVIP is the principal branded competitor and creates the main pricing and formulary risk.
- Conventional ANDA competition is less likely than competition from another complex antivenom product.
- Manufacturing, potency testing, animal-derived inputs, and regulatory validation are more significant barriers than basic patent exclusivity.
- No major publicly documented Paragraph IV litigation or CROFAB patent settlement is established in the cited sources.
- CROFAB’s commercial outlook is stable but exposed to ANAVIP adoption, hospital contracting, inventory costs, and supply reliability.
FAQs About CROFAB Market and Financial Outlook
Is CROFAB still FDA approved?
Yes. CROFAB remains an FDA-approved treatment for North American crotalid envenomation under NDA 020807.[1]
Who owns CROFAB?
SERB Pharmaceuticals owns the Specialty Pharmaceuticals business acquired from BTG, including CROFAB, following the 2021 transaction.[4]
Is CROFAB a biosimilar?
No. CROFAB is an animal-derived antibody-fragment antivenom approved as a drug under an NDA. It is not a biosimilar to ANAVIP.
What is the main commercial threat to CROFAB?
ANAVIP is the main commercial threat because it gives hospitals a branded alternative and may offer clinical and economic advantages linked to its longer antibody-fragment persistence.
Why is CROFAB expensive?
CROFAB requires specialized animal-derived manufacturing, venom sourcing, purification, potency testing, cold-chain distribution, and inventory maintenance for an emergency product with irregular utilization.
References
-
U.S. Food and Drug Administration. (2018). CROFAB: Crotalidae polyvalent immune Fab (ovine), prescribing information. FDA.
-
Centers for Disease Control and Prevention. (2024). Venomous snakes and snakebite prevention. CDC.
-
BTG plc. (2020). Annual report and accounts 2020. BTG plc.
-
SERB Pharmaceuticals. (2021). SERB Pharmaceuticals completes acquisition of BTG Specialty Pharmaceuticals. SERB Pharmaceuticals.
-
U.S. Food and Drug Administration. (2018). ANAVIP: Crotalidae immune F(ab')2 (equine), prescribing information. FDA.
